Wilkes NSG 533 Final Exam Comprehensive Advanced
Pharmacology Prep Document | 2026/2027 Edition | 150
Verified Questions - 140 Questions with Answers
Wilkes NSG 533 Final Exam 2026-140 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for Wilkes NSG 533 Final Exam offers 150 verified
questions and answers, meticulously aligned with the latest advanced pharmacology guidelines. Each
question is accompanied by detailed rationales and explanations to reinforce key concepts and clinical
applications. Designed for graduate nursing students, this resource ensures a thorough review of
pharmacotherapeutic principles, drug interactions, and patient-centered care. With a focus on
evidence-based practice, this document is an essential tool for achieving a top score on the final exam.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug interactions and adverse effects
Prescribing for special populations (pediatric, geriatric, pregnancy)
Clinical decision-making and patient education
Antimicrobial, cardiovascular, and psychotropic pharmacotherapy
Pain management and controlled substances
Updates for 2026:
- Updated to reflect 2026-2027 academic year guidelines
- Incorporates latest FDA approvals and black box warnings
- Revised rationales to align with current evidence-based practice
- Enhanced coverage of opioid prescribing and pain management protocols
- Added new questions on biologics and targeted therapies
Abstract:
This comprehensive exam preparation document for Wilkes NSG 533 Final Exam provides 150 verified questions
and answers, meticulously curated to reflect the advanced pharmacology curriculum for graduate nursing
students. The content encompasses a broad spectrum of topics, including pharmacokinetics, pharmacodynamics,
drug interactions, and therapeutic management across various patient populations. Each question is paired with a
detailed rationale that explains the correct answer and distractor analysis, facilitating deeper understanding and
retention. The document is updated to align with the 2026-2027 academic year, incorporating the latest clinical
guidelines and FDA approvals. Emphasis is placed on safe prescribing practices, patient education, and
interprofessional collaboration, ensuring that students are well-prepared for both the exam and clinical practice.
This resource serves as an indispensable tool for achieving a high score and demonstrating competency in
advanced pharmacology.
Keywords:
Advanced Pharmacology, NSG 533, Wilkes University, Exam Prep, Pharmacotherapeutics, Drug Interactions,
Nursing Education, 2026-2027
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying
pharmacological principles, and a brief analysis of why the incorrect options are not suitable. Rationales are written
in a clear, concise manner to reinforce learning and clinical application.
Page 1
,Compliance Checklist:
Aligned with the latest NCCN and AHA guidelines
Includes FDA-approved drug indications and safety warnings
Covers DEA controlled substance regulations
References evidence-based practice standards
Suitable for graduate-level nursing curriculum
Updated for the 2026-2027 academic year
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-20 Absorption, Distribution, Metabolism, 13%
Pharmacodynamics Excretion, Dose-Response
Autonomic and Cardiovascular 21-45 Adrenergic, Cholinergic, Antihypertensives, 17%
Pharmacology Antiarrhythmics, Anticoagulants
Neuropsychiatric Pharmacology 46-70 Antidepressants, Antipsychotics, 17%
Anxiolytics, Antiepileptics, Stimulants
Endocrine and Metabolic 71-90 Insulin, Oral Hypoglycemics, Thyroid, 13%
Pharmacology Corticosteroids, Osteoporosis
Antimicrobial and 91-115 Antibiotics, Antivirals, Antifungals, 17%
Anti-inflammatory NSAIDs, DMARDs
Pharmacology
Special Populations and Pain 116-135 Pediatric, Geriatric, Pregnancy, Opioids, 13%
Management Adjuvant Analgesics
Clinical Decision-Making and 136-150 Drug Interactions, Monitoring, Adherence, 10%
Patient Education Counseling, Legal/Ethical
Page 2
,Q1. A patient with a history of recurrent atrial fibrillation is prescribed digoxin.
Which interaction would most significantly increase the risk of digoxin toxicity?
A. Concurrent use of a loop diuretic causing hypokalemia
B. Concurrent use of an ACE inhibitor causing hyperkalemia
C. Concurrent use of a beta-blocker causing bradycardia
D. Concurrent use of a calcium channel blocker causing hypotension
Correct Answer: A. Concurrent use of a loop diuretic causing hypokalemia
Rationale: Hypokalemia from loop diuretics increases myocardial sensitivity to digoxin
and reduces its renal clearance, potentiating toxicity. Hyperkalemia (B) actually decreases
digoxin binding to Na+/K+-ATPase, reducing effect. Bradycardia (C) and hypotension (D)
are additive effects but not the primary toxicity risk.
Why Wrong:
B - Hyperkalemia decreases digoxin receptor binding, lowering risk of toxicity.
C - Bradycardia is a side effect but does not increase digoxin plasma levels.
D - Hypotension is a hemodynamic effect, not a direct cause of digoxin toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56.
Q2. A patient with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is
being treated with vancomycin. Which pharmacodynamic parameter best predicts
clinical efficacy for this antibiotic?
A. Time above the minimum inhibitory concentration (T>MIC)
B. Area under the curve to MIC ratio (AUC/MIC)
C. Peak concentration to MIC ratio
D. Post-antibiotic effect duration
Correct Answer: B. Area under the curve to MIC ratio (AUC/MIC)
Rationale: Vancomycin is a concentration-dependent antibiotic with time-dependent
killing; AUC/MIC ratio is the best predictor of efficacy, with target 400. T>MIC (A) is
more relevant for beta-lactams. Peak/MIC (C) is for aminoglycosides. Post-antibiotic effect
(D) is a property but not the primary predictor.
Why Wrong:
A - T>MIC is the primary parameter for beta-lactams, not vancomycin.
C - Peak/MIC is used for aminoglycosides, not vancomycin.
D - Post-antibiotic effect is not the main efficacy predictor for vancomycin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82.
Q3. Which medication requires dosage adjustment in a patient with hepatic
impairment due to its extensive first-pass metabolism, and why?
A. Morphine: active metabolite accumulation
Page 3
, B. Warfarin: increased protein binding
C. Lidocaine: reduced hepatic extraction
D. Acetaminophen: saturation of conjugation pathways
Correct Answer: C. Lidocaine: reduced hepatic extraction
Rationale: Lidocaine undergoes extensive hepatic first-pass metabolism; in hepatic
impairment, its clearance is reduced, increasing toxicity risk. Morphine (A) has active
metabolites but is more affected in renal impairment. Warfarin (B) is highly protein-bound
but primarily renally cleared. Acetaminophen (D) conjugation is less affected in hepatic
disease.
Why Wrong:
A - Morphine's active metabolites accumulate in renal failure, not hepatic.
B - Warfarin's clearance is mainly hepatic but its dosing is guided by INR, not just
protein binding.
D - Acetaminophen metabolism is not significantly impaired in hepatic disease until
severe.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5.
Q4. A patient on clopidogrel for recent stent placement is started on omeprazole for
gastroprotection. Which genetic factor and drug interaction best explains the reduced
antiplatelet effect?
A. CYP2C19 poor metabolizer phenotype and enzyme inhibition by omeprazole
B. CYP3A4 induction by omeprazole increasing clopidogrel clearance
C. P-glycoprotein inhibition reducing clopidogrel absorption
D. CYP2C9 polymorphism decreasing active metabolite formation
Correct Answer: A. CYP2C19 poor metabolizer phenotype and enzyme inhibition by
omeprazole
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Omeprazole inhibits
CYP2C19, reducing activation. Patients who are CYP2C19 poor metabolizers already
have reduced activation; the interaction compounds this. CYP3A4 (B) is minor, P-gp (C)
affects absorption but not the main interaction, CYP2C9 (D) is not involved.
Why Wrong:
B - Omeprazole does not induce CYP3A4.
C - P-gp inhibition would increase absorption, not decrease antiplatelet effect.
D - CYP2C9 is not the primary enzyme for clopidogrel activation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 49.
Q5. A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) is
prescribed metformin. Which statement is most accurate regarding this therapy?
A. Metformin is contraindicated due to risk of lactic acidosis and should be
Page 4
Pharmacology Prep Document | 2026/2027 Edition | 150
Verified Questions - 140 Questions with Answers
Wilkes NSG 533 Final Exam 2026-140 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for Wilkes NSG 533 Final Exam offers 150 verified
questions and answers, meticulously aligned with the latest advanced pharmacology guidelines. Each
question is accompanied by detailed rationales and explanations to reinforce key concepts and clinical
applications. Designed for graduate nursing students, this resource ensures a thorough review of
pharmacotherapeutic principles, drug interactions, and patient-centered care. With a focus on
evidence-based practice, this document is an essential tool for achieving a top score on the final exam.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug interactions and adverse effects
Prescribing for special populations (pediatric, geriatric, pregnancy)
Clinical decision-making and patient education
Antimicrobial, cardiovascular, and psychotropic pharmacotherapy
Pain management and controlled substances
Updates for 2026:
- Updated to reflect 2026-2027 academic year guidelines
- Incorporates latest FDA approvals and black box warnings
- Revised rationales to align with current evidence-based practice
- Enhanced coverage of opioid prescribing and pain management protocols
- Added new questions on biologics and targeted therapies
Abstract:
This comprehensive exam preparation document for Wilkes NSG 533 Final Exam provides 150 verified questions
and answers, meticulously curated to reflect the advanced pharmacology curriculum for graduate nursing
students. The content encompasses a broad spectrum of topics, including pharmacokinetics, pharmacodynamics,
drug interactions, and therapeutic management across various patient populations. Each question is paired with a
detailed rationale that explains the correct answer and distractor analysis, facilitating deeper understanding and
retention. The document is updated to align with the 2026-2027 academic year, incorporating the latest clinical
guidelines and FDA approvals. Emphasis is placed on safe prescribing practices, patient education, and
interprofessional collaboration, ensuring that students are well-prepared for both the exam and clinical practice.
This resource serves as an indispensable tool for achieving a high score and demonstrating competency in
advanced pharmacology.
Keywords:
Advanced Pharmacology, NSG 533, Wilkes University, Exam Prep, Pharmacotherapeutics, Drug Interactions,
Nursing Education, 2026-2027
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying
pharmacological principles, and a brief analysis of why the incorrect options are not suitable. Rationales are written
in a clear, concise manner to reinforce learning and clinical application.
Page 1
,Compliance Checklist:
Aligned with the latest NCCN and AHA guidelines
Includes FDA-approved drug indications and safety warnings
Covers DEA controlled substance regulations
References evidence-based practice standards
Suitable for graduate-level nursing curriculum
Updated for the 2026-2027 academic year
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-20 Absorption, Distribution, Metabolism, 13%
Pharmacodynamics Excretion, Dose-Response
Autonomic and Cardiovascular 21-45 Adrenergic, Cholinergic, Antihypertensives, 17%
Pharmacology Antiarrhythmics, Anticoagulants
Neuropsychiatric Pharmacology 46-70 Antidepressants, Antipsychotics, 17%
Anxiolytics, Antiepileptics, Stimulants
Endocrine and Metabolic 71-90 Insulin, Oral Hypoglycemics, Thyroid, 13%
Pharmacology Corticosteroids, Osteoporosis
Antimicrobial and 91-115 Antibiotics, Antivirals, Antifungals, 17%
Anti-inflammatory NSAIDs, DMARDs
Pharmacology
Special Populations and Pain 116-135 Pediatric, Geriatric, Pregnancy, Opioids, 13%
Management Adjuvant Analgesics
Clinical Decision-Making and 136-150 Drug Interactions, Monitoring, Adherence, 10%
Patient Education Counseling, Legal/Ethical
Page 2
,Q1. A patient with a history of recurrent atrial fibrillation is prescribed digoxin.
Which interaction would most significantly increase the risk of digoxin toxicity?
A. Concurrent use of a loop diuretic causing hypokalemia
B. Concurrent use of an ACE inhibitor causing hyperkalemia
C. Concurrent use of a beta-blocker causing bradycardia
D. Concurrent use of a calcium channel blocker causing hypotension
Correct Answer: A. Concurrent use of a loop diuretic causing hypokalemia
Rationale: Hypokalemia from loop diuretics increases myocardial sensitivity to digoxin
and reduces its renal clearance, potentiating toxicity. Hyperkalemia (B) actually decreases
digoxin binding to Na+/K+-ATPase, reducing effect. Bradycardia (C) and hypotension (D)
are additive effects but not the primary toxicity risk.
Why Wrong:
B - Hyperkalemia decreases digoxin receptor binding, lowering risk of toxicity.
C - Bradycardia is a side effect but does not increase digoxin plasma levels.
D - Hypotension is a hemodynamic effect, not a direct cause of digoxin toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56.
Q2. A patient with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is
being treated with vancomycin. Which pharmacodynamic parameter best predicts
clinical efficacy for this antibiotic?
A. Time above the minimum inhibitory concentration (T>MIC)
B. Area under the curve to MIC ratio (AUC/MIC)
C. Peak concentration to MIC ratio
D. Post-antibiotic effect duration
Correct Answer: B. Area under the curve to MIC ratio (AUC/MIC)
Rationale: Vancomycin is a concentration-dependent antibiotic with time-dependent
killing; AUC/MIC ratio is the best predictor of efficacy, with target 400. T>MIC (A) is
more relevant for beta-lactams. Peak/MIC (C) is for aminoglycosides. Post-antibiotic effect
(D) is a property but not the primary predictor.
Why Wrong:
A - T>MIC is the primary parameter for beta-lactams, not vancomycin.
C - Peak/MIC is used for aminoglycosides, not vancomycin.
D - Post-antibiotic effect is not the main efficacy predictor for vancomycin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82.
Q3. Which medication requires dosage adjustment in a patient with hepatic
impairment due to its extensive first-pass metabolism, and why?
A. Morphine: active metabolite accumulation
Page 3
, B. Warfarin: increased protein binding
C. Lidocaine: reduced hepatic extraction
D. Acetaminophen: saturation of conjugation pathways
Correct Answer: C. Lidocaine: reduced hepatic extraction
Rationale: Lidocaine undergoes extensive hepatic first-pass metabolism; in hepatic
impairment, its clearance is reduced, increasing toxicity risk. Morphine (A) has active
metabolites but is more affected in renal impairment. Warfarin (B) is highly protein-bound
but primarily renally cleared. Acetaminophen (D) conjugation is less affected in hepatic
disease.
Why Wrong:
A - Morphine's active metabolites accumulate in renal failure, not hepatic.
B - Warfarin's clearance is mainly hepatic but its dosing is guided by INR, not just
protein binding.
D - Acetaminophen metabolism is not significantly impaired in hepatic disease until
severe.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5.
Q4. A patient on clopidogrel for recent stent placement is started on omeprazole for
gastroprotection. Which genetic factor and drug interaction best explains the reduced
antiplatelet effect?
A. CYP2C19 poor metabolizer phenotype and enzyme inhibition by omeprazole
B. CYP3A4 induction by omeprazole increasing clopidogrel clearance
C. P-glycoprotein inhibition reducing clopidogrel absorption
D. CYP2C9 polymorphism decreasing active metabolite formation
Correct Answer: A. CYP2C19 poor metabolizer phenotype and enzyme inhibition by
omeprazole
Rationale: Clopidogrel is a prodrug activated by CYP2C19. Omeprazole inhibits
CYP2C19, reducing activation. Patients who are CYP2C19 poor metabolizers already
have reduced activation; the interaction compounds this. CYP3A4 (B) is minor, P-gp (C)
affects absorption but not the main interaction, CYP2C9 (D) is not involved.
Why Wrong:
B - Omeprazole does not induce CYP3A4.
C - P-gp inhibition would increase absorption, not decrease antiplatelet effect.
D - CYP2C9 is not the primary enzyme for clopidogrel activation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 49.
Q5. A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) is
prescribed metformin. Which statement is most accurate regarding this therapy?
A. Metformin is contraindicated due to risk of lactic acidosis and should be
Page 4
